BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 8105115)

  • 1. [High-dose chemoradiotherapy combined with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by autologous peripheral blood stem cell transplantation (PBSCT) in a case of refractory acute myelogenous leukemia (AML)].
    Tanosaki R; Okamoto S; Takahashi S; Inoue T; Kikuno K; Aoki Y; Takada M; Irie S; Shimane M; Tojo A
    Rinsho Ketsueki; 1993 Aug; 34(8):946-51. PubMed ID: 8105115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
    Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse.
    Richard C; Baro J; Bello-Fernandez C; Hermida G; Calavia J; Olalla I; Alsar MJ; Loyola I; Cuadrado MA; Iriondo A
    Bone Marrow Transplant; 1995 May; 15(5):721-6. PubMed ID: 7670401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.
    Takahashi S; Okamoto SI; Shirafuji N; Ikebuchi K; Tani K; Shimane M; Matsudaira T; Irie S; Tsuruta T; Matsuishi E
    Bone Marrow Transplant; 1994 Mar; 13(3):239-45. PubMed ID: 7515298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful second autologous blood stem cell transplantation after G-CSF-combined conditioning for the treatment of high-risk acute myelogenous leukemia.
    Takamatsu Y; Teshima T; Akashi K; Inaba S; Harada M; Niho Y
    Bone Marrow Transplant; 1994 Mar; 13(3):325-7. PubMed ID: 7515302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
    Bernell P; Kimby E; Hast R
    Leukemia; 1994 Oct; 8(10):1631-9. PubMed ID: 7934158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
    Ippoliti C; Przepiorka D; Giralt S; Andersson BS; Wallerstein RO; Gutterman J; Deisseroth AB; Champlin RE
    Bone Marrow Transplant; 1993 Jan; 11(1):55-9. PubMed ID: 8094309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction.
    Lanza F; Rigolin GM; Castagnari B; Moretti S; Castoldi G
    Haematologica; 1997; 82(2):239-45. PubMed ID: 9175331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
    Herrmann F; Mertelsmann R; Lindemann A; Ottmann OG; Seipelt G; Oster W; Hoelzer D; Ganser A
    Biotechnol Ther; 1991; 2(3-4):299-311. PubMed ID: 1845132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome.
    Martín C; Torres A; León A; Rubio V; Alvarez MA; Herrera C; Jean-Paul E; Correa MA; Rojas R; Campos R; Serrano J; Romero R; Román J; Guzmán JL; Flores R; Falcón M; Martínez F; Gómez P
    Bone Marrow Transplant; 1998 Feb; 21(4):375-82. PubMed ID: 9509972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Enhanced sensitivity to cytosine arabinoside by combined stimulation of steel factor and GM-CSF in a factor-dependent leukemic cell line, MO7e--in terms of a possible clinical application to AML treatment].
    Gotoh A; Kawanishi Y; Kurosawa K; Miyazawa K; Ohtaka M; Aizawa S; Kimura Y; Yoshikawa O; Toyama K
    Rinsho Ketsueki; 1993 Jul; 34(7):821-8. PubMed ID: 7689660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of recombinant human GM-CSF to enhance peripheral progenitor cell yield for autologous transplantation.
    Ho AD; Haas R; Korbling M; Dietz M; Hunstein W
    Bone Marrow Transplant; 1991; 7 Suppl 1():13-7. PubMed ID: 1675138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
    Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S
    Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous blood progenitor cell transplantation in relapsed Hodgkin's disease--the role of haematopoietic growth factors.
    Haas R; Hohaus S; Ehrhardt R; Goldschmidt H; Hunstein W
    Bone Marrow Transplant; 1993; 11 Suppl 2():30-5. PubMed ID: 8101459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
    Colombat P; Delain M; Desbois I; Domenech J; Binet C; Tabah I; Lamagnere JP; Linassier C
    Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.